3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
3
Neoplasms
1
Leukemia
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
pirtobrutinib
3
Cyclophosphamide
3
Azacitidine
3
ibrutinib
2
fludarabine
2
Mycophenolic Acid
2
Lenalidomide
2
zanubrutinib
1
venetoclax
1
ruxolitinib
1
ponatinib
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine phosphate
1
cedazuridine
1
cc-486
1
asciminib
1
acalabrutinib
1
Whole-Body Irradiation
1
Vancomycin
1
Tretinoin
1
Tacrolimus
1
Sirolimus
1
Semen Analysis
1
Rituximab
1
Quality of Life
1
Physical Examination
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Arsenic Trioxide
×
90 days
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled